Shanghai, China Sinopharm Group appeared to be the Corporate Investor, which was created in 1998. The fund was located in Asia if to be more exact in China. The main office of represented Corporate Investor is situated in the Shanghai.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Sinopharm Group, startups are often financed by Versant Ventures, Tavistock Life Sciences, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are Northeast Securities, HOPU Investment Management Company, Everbright.
Considering the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016. The fund is generally included in less than 2 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund.
We can highlight the next thriving fund investment areas, such as Life Science, Beauty. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Ambrx, GemPharmatech Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
Related Funds
| Fund Name | Location |
| A5 Capital Partners | Brazil, São Paulo, Sao Paulo |
| Chengdu Kunde Touzi | Chengdu, China, Sichuan |
| Coats plc | Hillingdon, United Kingdom, Uxbridge |
| Denali Capital | - |
| ES-CON Japan | Japan, Minato |
| Javelin Venture Partners | California, San Francisco, United States |
| K Street Capital | District of Columbia, United States, Washington |
| MF Private Capital | Boston, Massachusetts, United States |
| Mitsubishi Corporation | Chiyoda, Japan |
| Montane Ventures | India, Maharashtra, Mumbai |
| Nakamo.to | - |
| Satya Capital | England, London, United Kingdom |
| Sharp | Japan, Toyama, Toyama Prefecture |
| Smithfield | Smithfield, United States, Virginia |
| Spike Ventures | California, Stanford, United States |
| Startups@KSTC | Kentucky, Louisville, United States |
| TPG Biotech | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
GemPharmatech | $24M | 02 Jul 2019 | Xuanwu District, Jiangsu, China | ||
| 07 Feb 2018 | Shangcheng District, Zhejiang, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
GemPharmatech | $24M | 02 Jul 2019 | Xuanwu District, Jiangsu, China | ||
| 07 Feb 2018 | Shangcheng District, Zhejiang, China |
